You can already now sign up for the event and send in your questions. You don’t have to participate live to submit questions for the event.
Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on 19 May at 10:00 AM when she presents the results for the first quarter of 2025.
During the quarter, Ascelia Pharma announced a positive outcome from its meeting with the FDA and confirmed its plan to submit the NDA for Orviglance in mid-2025. The company also determined the subscription price for warrant TO1 at SEK 2.15. Following the end of the quarter, Ascelia Pharma announced a subscription rate of approximately 96% for warrant TO1, resulting in gross proceeds of SEK 43 million.
Ascelia Pharma is a biotech company focused on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmo, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE)
Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup, 12.30, 23 April 2025.
